- Home
- » Tags
- » Lixisenatide
Top View
- Zealand Initiates First Phase 3 Trial with Dasiglucagon for the Treatment of Severe Hypoglycemia in Diabetes
- Injectables That Lower Glucose
- Therapeutic Class Overview Therapeuticincretin Mimeticsclass Overview & Amylinomimetics
- LIXISENATIDE and Iglarlixi (Insulin Glargine/Lixisenatide Fixed-Ratio Combination)
- Positive Phase 2A Results with Microdoses of Dasiglucagon Support Use in a Dual-Hormone Artificial Pancreas System
- New Analog Insulins … Are They Worth It ??
- Glucagon Like Peptide 1 Receptor Agonists: a Therapy for Diabetes
- Neuroprotective Effects of Lixisenatide and Liraglutide in the MPTP Mouse Model of Parkinson’S Disease
- 208673Orig1s000
- Lixisenatide (Lyxumia®) Prescribing Information Sheet – Updated November 2020
- 208471Orig1s000
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice
- Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes
- Suliqua, Frequent Glucose Monitoring and Dose Adjustment May Be Necessary
- Adlyxin (Lixisenatide) Vs. Victoza (Liraglutide) and Byetta (Exenatide) August 4, 2016
- Incretin Mimetics & Amylinomimetics
- Properties of GLP-1 Agonists and Their Use in Type 2 Diabetes
- GLP-1 Agonists Jostling for Position
- Adlyxin (Lixisenatide)
- Insulin and Injectable Therapy Posters and Abstracts from San Diego
- Allergic Reaction to Exenatide and Lixisenatide but Not to Liraglutide
- INSULIN GLP-1 COMBINATIONS Soliqua (Insulin Glargine and Lixisenatide), Xultophy (Insulin Degludec and Liraglutide)
- Dasiglucagon (Pinn) Presentation at the 77Th Scientific Sessions of the American Diabetes Association (ADA) Indicate Use for Treatment of Severe Hypoglycemia
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mortality and Cardiovascular Events: a Comprehensive Meta-Analysis of Randomized Controlled Trials
- Phase II Results with Dasiglucagon (ZP4207) Support Its Potential For
- ADLYXIN Pen Between Patients, Even If the Needle Is Changed These Highlights Do Not Include All the Information Needed to Use (5.3)
- Zealand Factsheet Zealand Pharma A/S Based in Denmark – Home to a World-Leading Healthcare Industry
- Lixisenatide: a New Glucagon-Like Peptide-1 Agonist Christopher W Ho* Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, USA
- IMPROVE GLYCEMIC CONTROL Helen Baron, MD, CCD Clinical Endocrinologist and Director of the Bone Mineral Density Unit at USC
- SOLIQUA 100/33 (Insulin Glargine
- Glucagon-Like Peptide-1 Analogs in the Treatment of Type 2 Diabetes: a Review of the Phase II and III Trials
- Senior / Principal Scientist in an Agile and Innovative Biotech Company
- Insulin Glargine and Lixisenatide Injection
- Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2
- Soliqua Solostar (Insulin Glargine and Lixisenatide) 1 Name of the Medicine
- Effects of Lixisenatide Versus Liraglutide (Short- and Long- Acting
- Insulin Glargine and Lixisenatide
- Insulin Glargine & Lixisenatide Injection
- Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St
- Lyxumia, INN-Lixisenatide
- Insulin Update: New and Emerging Insulins
- Diabetic Medications
- Cost-Effectiveness of Insulin Glargine/Lixisenatide Titratable Fixed
- Injectable Coformulations in Diabetology
- Lixisenatide: Clinical Profile and Available Evidence
- Pharmacologically Relevant Drug Interactions of Glucagon-Like Peptide-1 Receptor Agonists
- Therapeutic Class Overview Insulin and Combination Agents
- Once-Daily Liraglutide Versus Lixisenatide As Add-On to Metformin
- Product Monograph Including Patient Medication Information
- Insulin Glargine and Lixisenatide Injection), for Never Share a SOLIQUA 100/33 Prefilled Pen Between Patients, Even If the Subcutaneous Use Needle Is Changed
- Ozempic (Semaglutide) Rybelsus (Semaglutide) Tablets Soliqua (Insulin Glargine and Lixisenatide) Xultophy (Insulin Degludec and Liraglutide) Effective 01/01/2021
- Injectable Antidiabetic Agents Policy #: Rx.01.162
- Changing Lives with Next Generation Peptide Therapeutics